Entelos inks deal with Lilly

Shares of the UK's Entelos surged after the company reported a licensing pact with Eli Lilly. The pact covers access to Entelos' database of 630 drug profiles, which is used to test an experimental therapy's safety and toxicity. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.